id,url,date,headline,company,public
1,https://ir.89bio.com/news-releases/news-release-details/89bio-initiates-phase-3-enlighten-fibrosis-trial-pegozafermin,3/12/2024,89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis,89bio,1
2,https://ir.89bio.com/news-releases/news-release-details/89bio-announces-inducement-grant-under-nasdaq-listing-rule-0,3/8/2024,89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4),89bio,1
3,https://ir.89bio.com/news-releases/news-release-details/89bio-participate-leerink-partners-global-biopharma-conference,3/5/2024,89bio to Participate in the Leerink Partners Global Biopharma Conference,89bio,1
4,https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-participate-stifel-2024-cns-days,3/12/2024,Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days,Acumen Pharmaceuticals,1
5,https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-presents-sabirnetug-acu193-fluid,3/8/2024,Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting,Acumen Pharmaceuticals,1
6,https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-present-sabirnetug-acu193-fluid-biomarker,2/21/2024,Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting,Acumen Pharmaceuticals,1
7,https://ir.aslanpharma.com/news-releases/news-release-details/aslan-pharmaceuticals-announces-5-million-registered-direct,3/13/2024,ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering,ASLAN Pharmaceuticals,1
8,https://ir.aslanpharma.com/news-releases/news-release-details/aslan-pharmaceuticals-provides-trek-dx-study-update-and,3/11/2024,ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients,ASLAN Pharmaceuticals,1
9,https://ir.aslanpharma.com/news-releases/news-release-details/aslan-pharmaceuticals-announces-new-translational-data,3/6/2024,ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors,ASLAN Pharmaceuticals,1
